Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Elixinol Wellness ( (AU:EXL) ) has shared an update.
Elixinol Wellness Limited reported a 3.6% rise in revenue to $15.5 million for the year ended 31 December 2025, but its net loss attributable to owners widened sharply to $5.5 million, a 219.4% increase from the prior year. Basic and diluted loss per share deepened to 2.15 cents from 1.11 cents, and no dividends were paid or declared for either the current or previous financial periods.
The company’s balance sheet weakened, with net tangible assets per share falling from 0.13 cents to negative 0.36 cents, reflecting a swing in net tangible assets from $0.3 million to a deficit of $1.5 million. Despite the deteriorating financial position, Elixinol’s 2025 financial statements received an unmodified audit opinion, and the board formally authorised the release of the preliminary final report to the market.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
More about Elixinol Wellness
Elixinol Wellness Limited is a health and wellness company focused on plant-derived products, operating through a consolidated group structure. The business generates revenues from ordinary activities and is listed, reporting to shareholders under Australian corporate and accounting requirements.
Average Trading Volume: 766,139
Technical Sentiment Signal: Sell
Current Market Cap: A$4.14M
For an in-depth examination of EXL stock, go to TipRanks’ Overview page.